John Dingell actually said...
Now, one obstacle for ensuring comparable inspections of domestic and foreign facilities is a lack of complete and accurate information that FDA has on generic drug manufacturing establishments.
Context
Dingell identifies lack of information as a barrier to effective inspections.
02/08/2012